Generic Medicine Info
Should be taken with food.
Blood dyscrasias. Severe renal (including haemodialysis patients), and hepatic impairment (except in familial Mediterranean fever). Concomitant use with P-glycoprotein (P-gp) inhibitors or strong CYP3A4 inhibitors in patients with renal or hepatic impairment.
Special Precautions
Patient with CV disease, gastrointestinal disorders, corneal wounds or ulcers; abnormalities in blood counts. Mild to moderate renal and hepatic impairment. Elderly, children. Pregnancy and lactation. Debilitated patients. Not indicated as an analgesic to treat pain from other causes. Patient Counselling This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor CBC, serum uric acid, renal function, LFT. Monitor for signs and symptoms of blood dyscrasias.
Adverse Reactions
Significant: Myelosuppression (e.g. thrombocytopenia, leucopenia, granulocytopenia, agranulocytosis, aplastic anaemia, thrombocytopenia), neuromuscular toxicity including rhabdomyolysis, gastrointestinal symptoms (e.g. anorexia, nausea, vomiting, diarrhoea). Eye disorders: Delayed corneal wound healing. Gastrointestinal disorders: Abdominal pain, gastrointestinal haemorrhage. General disorders and administration site conditions: Fatigue. Investigations: Increased ALT/AST, elevated creatine phosphokinase. Musculoskeletal and connective tissue disorders: Myotonia, muscle weakness, myopathy. Nervous system disorders: Headache, neuropathy, peripheral neuritis. Reproductive system and breast disorders: Amenorrhoea, oligospermia, azoospermia. Respiratory, thoracic and mediastinal disorders: Pharyngolaryngeal pain. Skin and subcutaneous tissue disorders: Rash, alopecia.
Drug Interactions
Increased risk of myopathy and rhabdomyolysis with statins, fibrates, digoxin, ciclosporin. Increased plasma concentration with cimetidine and tolbutamide. May cause reversible malabsorption of vitamin B12. Concomitant use with phenylbutazone may increase risk of leucopenia, thrombocytopenia or bone marrow depression. NSAIDs may increase risk of gastrointestinal ulceration or haemorrhage. Reduced efficacy of prophylactic gout therapy with cytolytic antineoplastic agents.
ATC Classification
M04AC01 - colchicine ; Belongs to the class of preparations with no effect on uric acid metabolism. Used in the treatment of gout.
Disclaimer: This information is independently developed by CIMS based on colchicine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in